These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 13641559

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. V. Microbiologic studies of mode of action.
    MAXWELL RE, NICKEL VS.
    Antibiot Chemother (Northfield); 1957 Feb; 7(2):81-9. PubMed ID: 24544268
    [No Abstract] [Full Text] [Related]

  • 6. The effect of azaserine and 6-diazo-5-oxo-L-norleucine on the biosynthesis of inosinic acid de novo.
    BUCHANAN JM.
    Tex Rep Biol Med; 1957 Feb; 15(1):148-53. PubMed ID: 13409287
    [No Abstract] [Full Text] [Related]

  • 7. A comparative study of 6-diazo-5-oxo-L-norleucine and O-diazoacety-L-serine on sarcoma 180.
    CLARKE DA, REILLY HC, STOCK CC.
    Antibiot Chemother (Northfield); 1957 Dec; 7(12):653-71. PubMed ID: 24544598
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Potential anti-cancer agents--II. A proposed mechanism for the anti-cancer action of L-azaserine and 6-diazo-5-oxo-L-norleucine.
    BAKER BR.
    Biochem Pharmacol; 1959 Sep; 2():161-7. PubMed ID: 13795976
    [No Abstract] [Full Text] [Related]

  • 11. Chromatographic studies of purine metabolism. V. Inhibition mechanism of diazo-oxo-norleucine in wild-type and in diazo-oxo-norleucine-resistant Escherichia coli.
    TOMISEK AJ, REID MR.
    J Biol Chem; 1962 Mar; 237():807-11. PubMed ID: 13921756
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Resistance in L1210 ascites without change in concentrative uptake of o-diazoacetyl-L-serine or 6-diazo-5-oxo-L-norleucine.
    JACQUEZ JA, HUTCHISON DJ.
    Cancer Res; 1959 May; 19(4):397-401. PubMed ID: 13652124
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON).
    Kulkarni RM, Dakoulas EW, Miller KE, Terse PS.
    Toxicol Mech Methods; 2017 Sep; 27(7):518-527. PubMed ID: 28552037
    [Abstract] [Full Text] [Related]

  • 18. Effect of 6 diazo 5 oxo l-norleucine on the rat litter in utero.
    THIERSCH JB.
    Proc Soc Exp Biol Med; 1957 Jan; 94(1):33-5. PubMed ID: 13400863
    [No Abstract] [Full Text] [Related]

  • 19. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies.
    COFFEY GL, EHRLICH J, FISHER MW, HILLEGAS AB, KOHBERGER DL, MACHAMER HE, RIGHTSEL WA, ROEGNER FR.
    Antibiot Chemother (Northfield); 1956 Aug; 6(8):487-97. PubMed ID: 24544086
    [No Abstract] [Full Text] [Related]

  • 20. [Diazo derivates of amino acids and peptides as possible antineoplastic chemotherapeutic agents. III. Activity on Galliera sarcoma of 2 N-diazoacetyl derivatives of glycine in comparison with azaserine and DON].
    BALDINI L, BRAMBILLA G, MATTIOLI F.
    Boll Soc Ital Biol Sper; 1960 Nov 15; 36():1188-92. PubMed ID: 13686269
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.